Filing Flows › Madrigal Pharmaceuticals (MDGL) › Q2 2026 › vs Q1 2026
Madrigal Pharmaceuticals (MDGL) Q2 2026 vs Q1 2026 (quarter over quarter)
Madrigal Pharmaceuticals's revenue rose $52.9M (+17%) from $311M in Q1 2026 to $364M in Q2 2026.
Madrigal Pharmaceuticals, Q2 2026: revenue $364M (+71% year over year), operating margin -15.5%, net loss $57.9M, operating cash flow $23.3M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 5.2% | -55.0% | +60.3 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $364M | $311M | $52.9M | +17% |
| Net loss | $57.9M | $94.4M | −$36.5M | -39% |
| Costs & expenses | $422M | $406M | $16.5M | +4% |
| Operating costs | $421M | $404M | $16.5M | +4% |
| Interest & other, net | $1.6M | $1.7M | −$37K | -2% |
| Research & development | $91.2M | $109M | −$17.5M | -16% |
| SG&A | $289M | $269M | $20.9M | +8% |
| Other operating costs | $40.0M | $26.8M | $13.2M | +49% |
| Operating cash sources | $81.3M | −$73.0M | $154M | — |
| Depreciation & amortization | $381K | $386K | −$5K | -1% |
| Share-based compensation | $35.4M | $34.0M | $1.4M | +4% |
| Working capital & other | $45.5M | −$107M | $153M | — |
| Net loss absorbed | $57.9M | $94.4M | −$36.5M | -39% |
| Operating cash flow | $23.3M | −$167M | $191M | — |
| Free cash flow (OCF − capex) | $19.1M | −$171M | $190M | — |
| Capital expenditures | $4.3M | $3.8M | $404K | +10% |
Questions
How much did Madrigal Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Madrigal Pharmaceuticals's revenue rose $52.9M (+17%) from $311M in Q1 2026 to $364M in Q2 2026.